Synovial Sarcoma (Oncology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Synovial Sarcoma – Drugs In Development, 2021, provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape.

Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Synovial Sarcoma – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Synovial Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Synovial Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 17, 12, 1, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Synovial Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Synovial Sarcoma (Oncology).

– The pipeline guide reviews pipeline therapeutics for Synovial Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Synovial Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Synovial Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Synovial Sarcoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Synovial Sarcoma (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Synovial Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Accuronix Therapeutics Inc

Actuate Therapeutics Inc

Adaptimmune Therapeutics Plc

Advenchen Laboratories LLC

Apollomics Inc

Astellas Pharma Inc

BioAtla Inc

Biogenera SpA

C4 Therapeutics Inc

CoBioRes NV

Cue Biopharma Inc

Eli Lilly and Co

ENB Therapeutics LLC

Epizyme Inc

F. Hoffmann-La Roche Ltd

Foghorn Therapeutics Inc

GlaxoSmithKline Plc

Immunocore Holdings Plc

Incyte Corp

Inhibrx Inc

Jiangsu Hengrui Medicine Co Ltd

Karyopharm Therapeutics Inc

Lyell Immunopharma Inc

MediGene AG

Merck & Co Inc

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc

Ohara Pharmaceutical Co Ltd

OncoTherapy Science Inc

Pfizer Inc

Shanghai GeneChem Co Ltd

Shanghai Junshi Bioscience Co Ltd

Tactical Therapeutics Inc

Takara Bio Inc

United Immunity Co Ltd

Xiangxue Life Sciences

Table of Contents

Table of Contents

Introduction

Synovial Sarcoma - Overview

Synovial Sarcoma - Therapeutics Development

Synovial Sarcoma - Therapeutics Assessment

Synovial Sarcoma - Companies Involved in Therapeutics Development

Synovial Sarcoma - Drug Profiles

Synovial Sarcoma - Dormant Projects

Synovial Sarcoma - Discontinued Products

Synovial Sarcoma - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Synovial Sarcoma, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Synovial Sarcoma – Pipeline by Accuronix Therapeutics Inc, 2021

Synovial Sarcoma – Pipeline by Actuate Therapeutics Inc, 2021

Synovial Sarcoma – Pipeline by Adaptimmune Therapeutics Plc, 2021

Synovial Sarcoma – Pipeline by Advenchen Laboratories LLC, 2021

Synovial Sarcoma – Pipeline by Apollomics Inc, 2021

Synovial Sarcoma – Pipeline by Astellas Pharma Inc, 2021

Synovial Sarcoma – Pipeline by BioAtla Inc, 2021

Synovial Sarcoma – Pipeline by Biogenera SpA, 2021

Synovial Sarcoma – Pipeline by C4 Therapeutics Inc, 2021

Synovial Sarcoma – Pipeline by CoBioRes NV, 2021

Synovial Sarcoma – Pipeline by Cue Biopharma Inc, 2021

Synovial Sarcoma – Pipeline by Eli Lilly and Co, 2021

Synovial Sarcoma – Pipeline by ENB Therapeutics LLC, 2021

Synovial Sarcoma – Pipeline by Epizyme Inc, 2021

Synovial Sarcoma – Pipeline by F. Hoffmann-La Roche Ltd, 2021

Synovial Sarcoma – Pipeline by Foghorn Therapeutics Inc, 2021

Synovial Sarcoma – Pipeline by GlaxoSmithKline Plc, 2021

Synovial Sarcoma – Pipeline by Immunocore Holdings Plc, 2021

Synovial Sarcoma – Pipeline by Incyte Corp, 2021

Synovial Sarcoma – Pipeline by Inhibrx Inc, 2021

Synovial Sarcoma – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021

Synovial Sarcoma – Pipeline by Karyopharm Therapeutics Inc, 2021

Synovial Sarcoma – Pipeline by Lyell Immunopharma Inc, 2021

Synovial Sarcoma – Pipeline by MediGene AG, 2021

Synovial Sarcoma – Pipeline by Merck & Co Inc, 2021

Synovial Sarcoma – Pipeline by Millennium Pharmaceuticals Inc, 2021

Synovial Sarcoma – Pipeline by Mirati Therapeutics Inc, 2021

Synovial Sarcoma – Pipeline by Ohara Pharmaceutical Co Ltd, 2021

Synovial Sarcoma – Pipeline by OncoTherapy Science Inc, 2021

Synovial Sarcoma – Dormant Projects, 2021

Synovial Sarcoma – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Synovial Sarcoma, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports